Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C07K16/10

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2021/087015ENGINEERED ANTIBODIES TO HIV ENV
WO 06.05.2021
Int.Class A61K 39/42
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
42viral
Appl.No PCT/US2020/057816 Applicant INTERNATIONAL AIDS VACCINE INITIATIVE Inventor SOK, Devin
The present disclosure relates to anti-HIV Env antibodies and their use in the treatment or prevention of HIV/AIDS. In one aspect, provided herein are enhanced engineered anti-HIV Env antibodies that were derived from the PGDM1400 parent antibody using directed-evolution and yeast display. In one aspect, provided herein are pharmaceutical compositions comprising the enhanced engineered anti-HIV Env antibodies disclosed herein.
2.WO/2021/086953COMPOSITIONS AND METHODS FOR PROPHYLAXIS OF HIV
WO 06.05.2021
Int.Class A61P 31/18
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
18for HIV
Appl.No PCT/US2020/057720 Applicant GEORGIA TECH RESEARCH CORPORATION Inventor SANTANGELO, Philip J.
Prophylactic compositions for inhibiting or reducing HIV infection and methods of their use are provided. One embodiment provides an antibody or an antigen binding fragment thereof that specifically binds to an HIV protein, for example gp120, and inhibits or reduces the ability of the HIV virus to infect human cells. One embodiment provides a PGT121 antibody or antigen binding fragment thereof modified to contain a GPI membrane anchor, wherein the antibody specifically binds to an HIV protein. In some embodiments the GPI membrane anchor is in the heavy chain of the antibody or antigen fragment thereof. In some aspects the antibody or antigen binding fragment specifically to gp120 or gp41.
3.WO/2021/086899ANTI-HEMAGGLUTININ ANTIBODIES AND METHODS OF USE THEREOF
WO 06.05.2021
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/US2020/057635 Applicant REGENERON PHARMACEUTICALS, INC. Inventor BAUM, Alina
Provided herein are monoclonal antibodies, or antigen-binding fragments thereof, that bind to the influenza B hemagglutinin (HA) protein, pharmaceutical compositions comprising the antibodies and methods of use. The antibodies are useful for inhibiting or neutralizing influenza B virus activity, thus providing a means of treating or preventing influenza infection in humans. Also provided is the use of one or more antibodies that bind to the influenza B HA for preventing viral attachment and/or entry into host cells. The antibodies may be used prophylactically or therapeutically and may be used alone or in combination with one or more other anti-viral agents or vaccines.
4.WO/2021/086948MRNA-ENCODED ANTIBODIES FOR CONTRACEPTION
WO 06.05.2021
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/US2020/057713 Applicant GEORGIA TECH RESEARCH CORPORATION Inventor SANTANGELO, Philip J.
Non-hormonal contraception compositions and methods for contraception are provided. One embodiment provides an antibody or an antigen binding fragment thereof that specifically binds to one or more sperm antigens and inhibits the ability of antibody-bound sperm to fertilize an egg. Typically, the antibody is a monoclonal antibody, for example a human or humanized monoclonal antibody. In one embodiment, the antibody or antigen binding fragment thereof specifically binds to CD52g expressed on vertebrate, for example human, sperm cells and inhibits, blocks, or reduces the ability of the antibody-bound sperm to fertilize an egg. In one embodiment the antibody contains a membrane anchor. The membrane anchor can contain transmembrane domains, glycosylphosphatidylinositol anchors, or myristoylation motifs.
5.WO/2021/076559HUMAN BROADLY NEUTRALIZING ANTIBODIES AGAINST THE MEMBRANE-PROXIMAL EXTERNAL REGION OF HIV ENV FOR VACCINE DESIGN AND INTERVENTION
WO 22.04.2021
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/US2020/055486 Applicant THE SCRIPPS RESEARCH INSTITUTE Inventor ZWICK, Michael
The present disclosure relates to anti-HIV antibodies and their use in the treatment or prevention of HIV/AIDS and in the development of HIV vaccines.
6.20210115115HUMAN WEST NILE VIRUS ANTIBODIES AND METHODS OF USE THEREFOR
US 22.04.2021
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No 17041790 Applicant Vanderbilt University Inventor James E. Crowe, Jr.

The present disclosure is directed to antibodies binding to and neutralizing West Nile virus and methods for use thereof.

7.112680421具有广谱性中和猪流行性腹泻病毒的单克隆抗体及其应用
CN 20.04.2021
Int.Class C12N 5/20
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
10Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
12Fused cells, e.g. hybridomas
16Animal cells
18Murine cells, e.g. mouse cells
20one of the fusion partners being a B lymphocyte
Appl.No 202110136987.X Applicant 中国农业科学院哈尔滨兽医研究所(中国动物卫生与流行病学中心哈尔滨分中心) Inventor 冯力
本发明公开了一株具有广谱性中和猪流行性腹泻病毒的单克隆抗体及其应用。所述的单克隆抗体是由保藏编号为CGMCC No.13840的杂交瘤细胞分泌产生。所述的单克隆抗体具有广谱性,能够有效中和PEDV‑LNCT2、PEDV‑LNSY和PEDV‑Hjms等G2基因亚型毒株,使其失去感染细胞的能力,也能够中和CV777毒株(G1基因亚型)。鉴于该单克隆抗体的生物学特性以及所具有的广谱性中和PEDV毒株的能力,该单克隆抗体可用于建立一系列包括阻断ELISA、捕获ELISA、间接ELISA、竞争ELISA和胶体金试纸条等方法在内的PEDV诊断方法,具备广阔的应用价值和研究价值。
8.112679605针对新型冠状病毒核衣壳蛋白的抗体或其抗原结合片段及其应用
CN 20.04.2021
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No 202110273293.0 Applicant 安源医药科技(上海)有限公司 Inventor 李强
本发明提供了一种针对新型冠状病毒核衣壳蛋白的抗体或其抗原结合片段及其应用,所述抗体选自mAb6抗体、mAb7抗体、mAb8抗体和mAb9抗体中的任意一种;且所述抗体由保藏号为CCTCC NO:C2020236、CCTCC NO:C2020237、CCTCC NO:C2020238或CCTCC NO:C2020239的杂交瘤细胞分泌。利用所述抗体能够检测环境样品和/或生物样品中新型冠状病毒或者其抗原的存在情况。此外,本发明还提供了利用所述抗体制备得到的新型冠状病毒检测试剂盒,能够在感染病毒早期就检测出核衣壳蛋白,为临床检测新型冠状病毒提供了快速、准确的手段。
9.112661841一种中和新冠病毒新表位的全人单克隆抗体17-2及其应用
CN 16.04.2021
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No 202011406812.8 Applicant 广州市第八人民医院 Inventor 庾蕾
本发明属于生物技术领域,具体涉及一种中和新冠病毒新表位的全人单克隆抗体17‑2及其应用。本发明通过B细胞培养及单克隆抗体技术,成功筛选出针对S2的中和抗体17‑2。本发明提供的抗体17‑2,可与S蛋白及S2结合,其EC50分别为0.034μg/ml和0.038μg/mL,可有效中和SARS‑CoV‑2病毒。与其它表位的S1‑RBD和S1‑NTD抗体联合应用于SARS‑CoV‑2感染的预防和治疗。
10.WO/2021/069487ANTIBODIES AGAINST INFECTIOUS PATHOGENS AND METHOD FOR PRODUCTION THEREOF
WO 15.04.2021
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/EP2020/078109 Applicant UNIVERSITÄT ZU KÖLN Inventor KLEIN, Florian
The present invention relates to a method for obtaining monoclonal human antibodies directed against an infectious pathogen, monoclonal human antibodies or binding fragments thereof which are directed against an infectious pathogen as obtained by the method of the invention, a pharmaceutical composition comprising such monoclonal human antibodies, a kit comprising such antibodies, and the monoclonal antibodies or binding fragments thereof and the pharmaceutical composition and the kit for use as a medicament and in the treatment or prevention of a disease caused by the infectious pathogen.